ReviewThe Journal of clinical endocrinology and metabolism2025
Approach to the Patient With Primary Aldosteronism: Role of Molecular Imaging.
Review in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Agreement Between Molecular Imaging and Adrenal Vein Sampling for Localization in Primary Aldosteronism: A Systematic Review.Journal of the American Heart Association · 2026Pooled it
- Real world experience with [Frontiers in endocrinology · 2026Article
- Primary aldosteronism beyond laterality: integrating subtype assignment with outcome-oriented risk stratification.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A common yet underdiagnosed cause of secondary hypertension, primary aldosteronism (PA) is characterized by excess aldosterone production, causing hypertension with increased risk of cardio-renal-metabolic complications. Accurate and timely localization of the source of aldosterone excess is crucial for management, in the form of curative adrenalectomy for unilateral aldosterone-producing adenoma or medical management for bilateral adrenal hyperplasia. The current diagnostic algorithm involves adrenal vein sampling (AVS) as the current "gold standard" in determining lateralization of aldosterone secretion, but its technical challenges present significant barriers to timely diagnosis and treatment. Recent technological advancements have contributed to the evolution of molecular imaging modalities such as 11C-metomidate positron emission tomography-computed tomography (11C-MTO PET-CT). Improved molecular imaging modalities hold significant potential to complement existing diagnostic pathways and refine treatment strategies for PA. This review evaluates different case scenarios comparing the utility of AVS with 11C-MTO PET-CT, suggesting a practical approach for its interpretation and highlighting the clinical decision-making process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.